INVIVO THERAPEUTICS HOLDINGS CORP.: Nasdaq/NYSE listing notice — InVivo Therapeutics receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until May 29, 2024

INVIVO THERAPEUTICS HOLDINGS CORP.

Company's common stock bid price closed below $1.00 per share for 30 consecutive business days.
Initial 180-day compliance period ends May 29, 2024; must close at $1.00+ for 10 consecutive days.
If compliance not achieved, Nasdaq may delist; company can appeal to Listing Qualifications Panel.
Company may be eligible for an additional 180-day cure period if it meets other listing standards.
Options considered include monitoring bid price and potential reverse stock split to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

INVIVO THERAPEUTICS HOLDINGS CORP. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 1, 2023, InVivo Therapeutics Holdings Corp. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has be

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-122862

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.